Phathom Pharmaceuticals is a biopharmaceutical company developing and commercializing treatments for gastrointestinal diseases, including its acid-suppression drug vonoprazan.
| Filer | 13FScore | This quarter | Shares | Value | % of their book |
|---|---|---|---|---|---|
| Steve Cohen / Point72 | 75 | New buy | 1,022,193 | $11,090,794 | 0.0% |
| Carlyle Group Inc. (auto-surfaced) | 44 | Holds (flat) | 3,496,808 | $37,940,367 | 0.4% |
Every tracked holder of this name, sorted new → added → flat → trimmed. Shares = reported 13F share count; Value as reported (a few managers file values in $thousands). Generated 2026-10-17.